ISEC Healthcare (40T) Q2 2026 earnings summary

Executive summary

• Revenue rose 9% year-over-year to $41.07 million for 1H2026, driven by growth in specialised and general health services, with Malaysia operations contributing significantly.

• Net profit declined 10% year-over-year to $6.16 million, mainly due to higher cost of sales and increased administrative expenses from new centre openings and staff costs.

• Gross profit margin decreased to 41.2% from 44.8% due to inflation in consumables and higher doctor remuneration.

• Expansion continued with new centres in Seremban and Batu Pahat, and ongoing development of the New KL Medical Centre.

Financial highlights

• Revenue: $41.07 million (+9% YoY); Specialised health services: $39.12 million (+9% YoY); General health services: $1.95 million (+6% YoY).

• Net profit: $6.16 million (-10% YoY); Profit attributable to owners: $6.23 million (-8% YoY).

• Gross profit: $16.93 million (flat YoY); Gross margin: 41.2% (down from 44.8%).

• Administrative expenses: $8.36 million (+10% YoY); Cost of sales: $24.14 million (+16% YoY).

• Earnings per share: 1.08 cents (basic and diluted, -8% YoY).

Outlook and guidance

• New KL Medical Centre expected to commence operations by 2027, with additional bank loan drawdowns secured for capital expenditure.

• ISEC Seremban and Batu Pahat centres are on track to begin operations in late 2026 and Q4 2026, respectively, pending regulatory approvals.

• No interim dividend declared for 1H2026 to preserve liquidity and support expansion.